Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
capecitabine + lurbinectedin
- Development stage
- Unknown
- Lead developer
- PharmaMar
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination therapy consisting of the oral fluoropyrimidine capecitabine and the synthetic alkaloid lurbinectedin. Lurbinectedin works by binding to DNA, generating double-strand breaks, and disrupting DNA-dependent transcription by inhibiting RNA polymerase II activity. Capecitabine is converted to 5-fluorouracil in tumor tissues. Preclinical studies showed synergistic effects between these agents against solid tumors.
02
Targets
Pol II (RNA polymerase II elongation factors)DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on capecitabine + lurbinectedin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on capecitabine + lurbinectedin.